Bay Street News, June, 2024

TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) — COMPUTEX — NVIDIA today announced the general availability of NVIDIA ACE generative AI microservices […]

Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a […]

In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved […]

CALGARY, Alberta, June 01, 2024 (GLOBE NEWSWIRE) — Prospera Energy Inc. (“Prospera” or the “Corporation“) (PEI: TSX-V; OF6A: FRA) 2023 […]

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall […]

An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for […]

SOLANA BEACH, Calif., June 01, 2024 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, […]

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical […]

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical […]

KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including […]